<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477359</url>
  </required_header>
  <id_info>
    <org_study_id>UOHI-04</org_study_id>
    <nct_id>NCT01477359</nct_id>
  </id_info>
  <brief_title>Cardiac Sarcoidosis Multi-Center Prospective Cohort</brief_title>
  <acronym>CHASM-CS</acronym>
  <official_title>Cardiac Sarcoidosis Multi-Center Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Ministry of Health and Long Term Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS)&#xD;
      of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A&#xD;
      Canadian physician survey found that most physicians do not investigate for CS as a&#xD;
      possibility in these situations. Thus many patients with clinically important CS are going&#xD;
      un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients'&#xD;
      leads to significant mortality and morbidity.&#xD;
&#xD;
      There are no published clinical consensus guidelines on treatment of CS. Corticosteroid&#xD;
      therapy is advocated by most experts. This is based on very modest data from small&#xD;
      retrospective observational studies using variable definitions of clinical response. The&#xD;
      effect of corticosteroid treatment on the clinical course of CS has not been studied in&#xD;
      prospective studies and will be one of the aims of this project. Recent physician surveys&#xD;
      regarding CS, in Canada and the US, found that current clinical practice varies widely. The&#xD;
      2008 American College of Cardiology/American Heart Association/Heart Rhythm society&#xD;
      guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent&#xD;
      sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.&#xD;
&#xD;
      A multi-center collaborative approach to study CS is greatly needed.&quot; The investigators&#xD;
      propose exactly that i.e. a multi-center prospective cohort to start to answer clinical&#xD;
      questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The&#xD;
      group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists,&#xD;
      cardiac imaging specialists with extensive experience in imaging of sarcoidosis and&#xD;
      biostatisticians. The research will be in two phases; a registry of current diagnostic&#xD;
      approaches, treatment and prognosis, and a randomized clinical trial of the effect of&#xD;
      corticosteroid treatment on the clinical course of cardiac sarcoidosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram,&#xD;
      ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan,&#xD;
      cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or&#xD;
      extra-cardiac).&#xD;
&#xD;
      Follow-up and clinical management of clinically manifest patients diagnosed with CS will&#xD;
      occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be&#xD;
      annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy&#xD;
      will be at the discretion of the treating physician.&#xD;
&#xD;
      Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened&#xD;
      for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac&#xD;
      MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be&#xD;
      followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is&#xD;
      negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence&#xD;
      of CS and be in the control group. They will be contacted at 5 years and at the time of study&#xD;
      completion.&#xD;
&#xD;
      All patients will be followed until the last patient recruited has been followed for 4 years.&#xD;
&#xD;
      The occurrence of the primary and secondary outcomes will be assessed in treated and&#xD;
      untreated patients.&#xD;
&#xD;
      There will be 2 imaging core labs. The PET core lab will be located at UOHI under the&#xD;
      direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr.&#xD;
      Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians&#xD;
      who are blinded to the clinical details of the patients.&#xD;
&#xD;
      The Biomarker core lab will be at The University of Ottawa Heart Institute under the&#xD;
      leadership of Dr P Liu.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically Manifest Patients</measure>
    <time_frame>On active therapy for 6 months</time_frame>
    <description>&quot;Clinically improved&quot; if they are alive and not had a heart transplant and have not had heart failure hospitalization and no sustained VT/VF and meet one or more of following&#xD;
(i) No sustained VT (if presented with sustained VT) (ii) Improvement in LV function (defined as 10% decrease in LV end systolic volume or 5% absolute increase in LVEF) (iii) Resolution of conduction system disease (if presented with sustained heart block)&#xD;
failure hospitalization and have not had sustained VT and one or both of: a. LV function improvement (defined as 10% decrease in LV end systolic volume) b. Resolution of conduction system disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically Silent and Control Patients</measure>
    <time_frame>9 years</time_frame>
    <description>Cardiac death or cardiac transplantation or sustained VT/VF or sustained second or third degree AV block or development of clinical congestive heart failure (with documented LVEF &lt; 50%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total mortality</measure>
    <time_frame>6 months and 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular mortality</measure>
    <time_frame>6 months and 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart failure hospitalization</measure>
    <time_frame>6 months and 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in LVEF from baseline</measure>
    <time_frame>6 months and 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in disease activity as assessed by PET imaging</measure>
    <time_frame>6 months and 60 months</time_frame>
    <description>comparing pre-treatment to 6 month scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation burden</measure>
    <time_frame>6 months and 60 months</time_frame>
    <description>from defibrillator diagnostics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular arrhythmia burden</measure>
    <time_frame>6 months and 60 months</time_frame>
    <description>from defibrillator diagnostics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of ventricular pacing</measure>
    <time_frame>6 months and 60 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Cardiac Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>CS screened as underlying etiology</arm_group_label>
    <description>Patients with active Clinically Manifest CS&#xD;
Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Frozen plasma, serum and buffy coat.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Electrophysiology Service patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To diagnose Clinically Manifest CS all following criteria must be met:&#xD;
&#xD;
        (i) Positive biopsy* for Sarcoid (either EMB or extra-cardiac) AND/OR (ii) CT Chest highly&#xD;
        suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical&#xD;
        features:&#xD;
&#xD;
          -  advanced conduction system disease (sustained Mobitz II AV block or third degree AV&#xD;
             block)&#xD;
&#xD;
          -  non- sustained or sustained ventricular arrhythmia&#xD;
&#xD;
          -  ventricular dysfunction (LVEF &lt; 50% and/or RVEF &lt; 40%) AND (iv) No alternative&#xD;
             explanation for clinical features AND (v) FDG-PET suggestive of active CS&#xD;
&#xD;
        To diagnose clinically silent CS all of the following criteria must be met&#xD;
&#xD;
        (i) Biopsy proven extra-cardiac sarcoidosis&#xD;
&#xD;
        AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis&#xD;
&#xD;
        AND (iii) CMR suggestive of cardiac sarcoidosis&#xD;
&#xD;
        AND (iv) Does not have criteria for clinically manifest CS ie. should not have any of&#xD;
        following&#xD;
&#xD;
          -  advanced conduction system disease (sustained Mobitz II AV block or third degree AV&#xD;
             block)&#xD;
&#xD;
          -  non- sustained or sustained ventricular arrhythmia&#xD;
&#xD;
          -  ventricular dysfunction (LVEF &lt; 50% and/or RVEF &lt; 40%)&#xD;
&#xD;
        Patients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no&#xD;
        evidence of CS' and followed as control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unable or unwilling to provide informed consent&#xD;
&#xD;
          -  patients who are pregnant or lactating&#xD;
&#xD;
          -  patients with known claustrophobia&#xD;
&#xD;
          -  age &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Birnie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Nery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rob Beanlands, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen MacDonald, RN, BPE</last_name>
    <phone>613-696-7000</phone>
    <phone_ext>17077</phone_ext>
    <email>kmacdonald@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Birnie, MD</last_name>
    <phone>613-696-7269</phone>
    <email>dbirnie@ottawaheart.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute of Alberta</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell Quinn, MD</last_name>
    </contact>
    <investigator>
      <last_name>Russell Quinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomascz Hruczkowski, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tomascz Hruczkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanta Chakrabarti, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shanta Chakrabarti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciorsti MacIntyre, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ciorsti MacIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Healey, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Gerard Cox, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jeff Healey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorne Gula, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lorne Gula, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernice Tsang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bernice Tsang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen MacDonald, RN BPE</last_name>
      <phone>613-696-7000</phone>
      <phone_ext>17077</phone_ext>
      <email>kmacdonald@ottawaheart.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tammy Knight</last_name>
      <phone>613-696-7000</phone>
      <phone_ext>19080</phone_ext>
      <email>tknight@ottawaheart.ca</email>
    </contact_backup>
    <investigator>
      <last_name>David Birnie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Dorian, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paul Dorian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Ha, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Ha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lena Rivard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lena Rivard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l&quot;Universite de Montreal-Hotel Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Fleury, RN</last_name>
    </contact>
    <investigator>
      <last_name>Benoit Coutu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiorella Rafti</last_name>
    </contact>
    <investigator>
      <last_name>Martin L Bernier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Vascular Research Inc-Regina General Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4P 0W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendra Townsend</last_name>
      <email>Ktownsend.pvri@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andrea Lavoie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hokkaido University</name>
      <address>
        <city>Sapporo</city>
        <zip>060-8638</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ichizo Tsujino, MD</last_name>
      <phone>81-11-706-5911</phone>
      <email>itsujino@med.hokudai.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Ichizo Tsujino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 10, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

